Investigation of iodine dose effect on aortic and liver enhancement in abdominal CT and on coronary artery enhancement in cardiac CT in daily medical practice

Investigation of iodine dose effect on aortic and liver enhancement in abdominal CT and on coronary artery enhancement in cardiac CT in daily medical practice - Iopamiron Abdominal and Cardiac CT enhancement study (IOPAC study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008219

Enrollment

2800

Registered

2012-07-01

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma coronary infarction

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients who undergo either abdominal CT or coronary CT using Iopamiron Injection 300 or 370 (intravenous injection) (2) Either outpatients or inpatients (3) Either male or female (4) Those between the age of 20 years<= and <85 years (5) Those having a clear consciousness

Exclusion criteria

Exclusion criteria: (Exclusion criteria both abdominal and coronary CT) (1) With a past history of anaphylaxis to iodine and iodined contrast media (2) Serious thyroid disease (3) Women during pregnancy or lactation (4) eGFR less than 45mL/min (5) Patient who the doctor in charge judges are ineligible for the study (Exclusion criteria in the case of abdominal CT) (6) Those who underwent liver invasive therapy(ope/RFA/TAE etc.) within 3 months (Exclusion criteria in the case of coronary CT) (7) Severe cardiac arrest (8) Severe valve disease (9) Patient who underwent CABG surgery

Design outcomes

Primary

Measure	Time frame
(1) Correlation between the contrast enhancement of the sites below and the dose of iodine according to various body size-related indices, such as sex, height, weight, lean body weight (LBW), body surface area (BSA) and body mass index (BMI), Abdominal CT Aortic enhancement in arterial phase Liver parenchyma enhancement in portal venous phase Coronary CT CT value at the left main trunk and right coronary artery after administration of Iopamiron (2) Correlation between good-enhancement and factors affecting the CT enhancement (Definition of good-enhancement) Abdominal CT Aortic enhancement in arterial phase is 280 HU or more Liver parenchyma enhancement in portal venous phase is 50 HU or more Coronary CT CT value of the coronary artery (LMT, RCA) after administration of Iopamiron is 325 HU or more	—

Measure

Time frame

(1) Correlation between the contrast enhancement of the sites below and the dose of iodine according to various body size-related indices, such as sex, height, weight, lean body weight (LBW), body surface area (BSA) and body mass index (BMI), Abdominal CT Aortic enhancement in arterial phase Liver parenchyma enhancement in portal venous phase Coronary CT CT value at the left main trunk and right coronary artery after administration of Iopamiron (2) Correlation between good-enhancement and factors affecting the CT enhancement (Definition of good-enhancement) Abdominal CT Aortic enhancement in arterial phase is 280 HU or more Liver parenchyma enhancement in portal venous phase is 50 HU or more Coronary CT CT value of the coronary artery (LMT, RCA) after administration of Iopamiron is 325 HU or more

—

Secondary

Measure	Time frame
Correlation between the contrast enhancement (HU) and visual assessment Correlation between the contrast enhancement of liver(HU) and liver function Adverse effects	—

Countries

Japan

Contacts

Public ContactDaisuke Utsunomiya

Kumamoto University Department of Radiology

utsunomi@kumamoto-u.ac.jp0963735261

Outcome results